Profile data is unavailable for this security.
About the company
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).
- Revenue in USD (TTM)0.00
- Net income in USD-8.50m
- Incorporated2009
- Employees1.00
- LocationTuHURA Biosciences Inc9920 Pacific Heights BlvdSuite 150, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 350-4364
- Fax+1 (604) 202-1384
- Websitehttps://www.kintara.com/
More ▼
Mergers & acquisitions
| Acquired company | HURA:NAQ since announced | Transaction value |
|---|---|---|
| TuHURA Biosciences Inc | 79.49% | -- |
Data delayed at least 15 minutes, as of Oct 18 2024 20:58 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IN8BIO, Inc. | 0.00 | -31.96m | 10.77m | 31.00 | -- | 0.7844 | -- | -- | -0.8357 | -0.8357 | 0.00 | 0.2933 | 0.00 | -- | -- | 0.00 | -122.41 | -74.18 | -146.35 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0945 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 10.84m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -24.92m | 11.08m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -28.90m | 11.20m | 42.00 | -- | 0.7251 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Jaguar Health Inc | 10.19m | -35.67m | 11.37m | 49.00 | -- | 0.5695 | -- | 1.12 | -41.34 | -41.34 | 6.62 | 2.48 | 0.1793 | 0.231 | 7.56 | 207,857.10 | -63.73 | -95.29 | -110.34 | -163.54 | 79.79 | 67.28 | -355.51 | -522.28 | 1.60 | -3.45 | 0.6333 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| BioRestorative Therapies Inc | 174.10k | -8.00m | 11.64m | 11.00 | -- | 1.08 | -- | 66.83 | -1.22 | -1.22 | 0.029 | 1.56 | 0.0118 | -- | 6.65 | 15,827.27 | -54.42 | -192.11 | -68.75 | -329.32 | 47.45 | -- | -4,597.79 | -19,116.15 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 43.67 | -- | 67.77 | -- |
| Dominari Holdings Inc | 9.51m | -22.02m | 11.80m | 26.00 | -- | 0.2771 | -- | 1.24 | -3.85 | -3.85 | 1.67 | 6.78 | 0.1629 | -- | 2.60 | 365,730.80 | -37.71 | -26.82 | -39.96 | -27.45 | -- | -- | -231.55 | -3,353.52 | -- | -5.05 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| GlucoTrack Inc | 0.00 | -12.05m | 11.89m | 6.00 | -- | -- | -- | -- | -2.42 | -2.42 | 0.00 | -0.6004 | 0.00 | -- | -- | 0.00 | -251.32 | -94.01 | -493.89 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | -- | -- | -- | -- | -60.02 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -8.50m | 11.99m | 1.00 | -- | -- | -- | -- | -2.15 | -2.15 | 0.00 | 0.0679 | 0.00 | -- | -- | 0.00 | -163.44 | -224.08 | -343.80 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| Correlate Energy Corp | 5.65m | -34.51m | 12.44m | 19.00 | -- | -- | -- | 2.20 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.33 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -12.75m | 12.92m | 29.00 | -- | -- | -- | -- | -3.36 | -3.36 | 0.00 | -0.6642 | 0.00 | -- | -- | 0.00 | -223.03 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 12.92m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.05m | 2.00 | 3.36 | 0.275 | 2.90 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.06m | 13.14m | 1.00 | -- | -- | -- | -- | -0.0017 | -0.0017 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -32.46 | -- | -46.53 | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | -- | -- | -14.64 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -1.24m | 13.16m | 22.00 | -- | 1.09 | -- | 188.05 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Data as of Oct 18 2024. Currency figures normalised to TuHURA Biosciences Inc's reporting currency: US Dollar USD
1.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Jun 2024 | 343.91k | 0.62% |
| G1 Execution Services LLCas of 30 Jun 2024 | 109.26k | 0.20% |
| UBS Securities LLCas of 30 Jun 2024 | 75.82k | 0.14% |
| XTX Markets LLCas of 30 Jun 2024 | 74.12k | 0.13% |
| Jane Street Capital LLCas of 30 Jun 2024 | 47.87k | 0.09% |
| Level Four Advisory Services LLCas of 30 Jun 2024 | 44.64k | 0.08% |
| Baader Bank AG (Investment Management)as of 30 Jun 2024 | 42.67k | 0.08% |
| Clear Creek Financial Management LLCas of 30 Jun 2024 | 27.50k | 0.05% |
| Integrated Wealth Concepts LLCas of 30 Jun 2024 | 22.00k | 0.04% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 12.46k | 0.02% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
